The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAngle Share News (AGL)

Share Price Information for Angle (AGL)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 14.50
Bid: 14.00
Ask: 15.00
Change: 0.50 (3.57%)
Spread: 1.00 (7.143%)
Open: 14.00
High: 15.00
Low: 14.00
Prev. Close: 14.00
AGL Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON MARKET MIDDAY: Retailers Next and JD Sports bookend FTSE 100

Thu, 04th Jan 2024 12:09

(Alliance News) - Stock prices in London were slightly higher at midday on Thursday, with the FTSE 100 looking set to snap the two-day losing streak it suffered at the start of the year.

Retailers Next and JD Sports were the best and worst performing blue-chip stocks respectively, after both provided trading updates including the Christmas period.

US stocks were called to open higher, following the release of minutes from the latest Federal Reserve meeting, and before the first of a pair of monthly US employment readings on Thursday.

The FTSE 100 index was up 7.08, or 0.1%, at 7,689.41. The FTSE 250 was up 14.33 points, 0.1%, at 19,340.73, and the AIM All-Share was up 0.28 of a point, marginally up, at 754.34.

The Cboe UK 100 was up 0.1% at 767.56, the Cboe UK 250 was up 0.2% at 16,806.97, and the Cboe Small Companies was up 0.4% at 14,916.62.

The UK service economy had its best performance in six months in December, a strong end to the year which helped boost the wider private sector, numbers showed.

The final S&P Global UK services business activity index climbed to 53.4 points in December from 50.9 in November. This was above the 50.0 no-change mark for the second month running and above the earlier flash estimate of 52.7

The final seasonally adjusted S&P Global UK composite purchasing managers' index registered 52.1 points in December, up from 50.7 in November and above the neutral 50.0 value for the second month running. This beat last month's flash estimate for December of 51.7 points and marked the highest final reading since June.

"The further rebound in December's PMI suggests a recession should be narrowly avoided," said Pantheon Macroeconomics analyst Gabriella Dickens.

In European equities on Thursday, the CAC 40 in Paris was up 0.4%, while the DAX 40 in Frankfurt was up 0.3%.

The eurozone service sector's decline slowed marginally in December, according to survey data from S&P Global.

The latest HCOB services purchasing managers' index posted 48.8 points in December, rising marginally from 48.7 in November and marking the fifth consecutive monthly contraction. The figure remained below the 50-point no-change mark, but registered above the flash estimate of 48.1 points.

S&P Global said demand for services fell at the end of the year, while sales and new business receipts also declined.

The HCOB eurozone composite PMI - a weighted average of the eurozone's manufacturing and services PMIs - posted 47.6 points in December, unchanged from November, and remaining below the 50-point threshold.

Sterling was quoted at USD1.2705 at midday on Thursday, higher than USD1.2646 at the London equities close on Wednesday. The euro traded at USD1.0958, higher than USD1.0915. Against the yen, the dollar was quoted at JPY144.19, up from JPY143.50.

In the FTSE 100, Next rose 4.7%. The retailer said full price sales during November and December were better than it anticipated.

In a trading update covering the nine weeks to December 30, Next said full price sales were up 5.7% from a year earlier, which was GBP39 million than its previous guidance of a 2.0% rise for the period.

Next upped its full-year pretax profit guidance by GBP20 million, or 4.0% to GBP905 million compared to last year, saying GBP17 million of the lift comes from the sales beat to date and GBP3 million from an upgraded forecast for full price sales in January.

JD Sports plunged 23%, after cutting its profit outlook amid weaker-than-expected sales growth and gross margins.

The retailer said organic revenue was up 6.0% in the 22 weeks that ended December 30 on a constant currency basis from a year earlier, with like-for-like growth of 1.8%. This was slightly behind its expectations. The retailer expects organic revenue growth of around 8% for the year ending February 3.

As a result, it expects to report pretax profit and adjusted items of between GBP915 million and GBP935 million for the financial year. This falls short of market expectations of GBP1.04 billion, which back in September, JD Sports had said it expected to meet.

"Our key markets have seen increased promotional activity during the peak trading season, driven by a more cautious consumer, but we continue to grow market share," said JD Sports Chief Executive Officer Regis Schultz.

"We are confident in our strategy and we continue to invest in our supply chain, systems and stores, supported by our strong cash generation and healthy balance sheet."

Oil majors BP and Shell rose 1.8% and 0.9% respectively, tracking higher oil prices. Brent oil bought USD78.87 a barrel early Thursday, higher than USD78.13 on Wednesday, as traders assess latest developments in the Middle East.

"The region remains a tinder box due to the Israel-Gaza war, and disruption to shipping routes through the Red Sea is also a key factor behind the surge in crude," AJ Bell analyst Russ Mould commented.

Among London's small-cap stocks, Topps Tiles lost 7.0%.

The retailer said sales in the 13 weeks ended December 30 were down 4.0% from a year earlier, with like-for-like sales down 7.1%.

It explained that trading in the first quarter reflected the ongoing challenges to discretionary consumer spending, particularly those impacting on businesses serving the repair, maintenance and improvement sector.

Topps Tiles expects its full-year profit to be weighted towards the second half, based on a number of factors including the timing of the holiday pay accrual, higher energy usage in the first half and general trading in the first half.

On AIM, Angle soared 66%, after it unveiled "breakthrough" clinical results from DNA molecular analysis of cancer patient blood samples that "provide a unique insight into the progression of each patient's cancer and how this may be treated".

The medical diagnostics firm said the results "highlight the potential for the Parsortix system to identify key variants [of] DNA mutations missed by other approaches to help guide treatment decisions."

Stocks in New York were called higher. The Dow Jones Industrial Average, the S&P 500 index up and the Nasdaq Composite were all called up 0.2%.

On the US data calendar on Thursday, there is the ADP jobs report at 1315 GMT, a precursor to Friday's nonfarms. The latest initial jobless claims reading is at 1330 GMT, before a services PMI at 1445 GMT.

The data comes after minutes from the Federal Reserve's latest meeting were released overnight.

"Yesterday's FOMC minutes brought a little bit of something for everyone, with members expressing caution as they attempt to drive inflation back down to target. While they currently do not see any upside risk to inflation, there is a concern that they could stall the current disinflation should they pivot too swiftly. Nonetheless, the key takeaway is that they are looking at the six-month metric for the core PCE, which has already dropped below 2%," Scope Markets analyst Joshua Mahony commented.

"With that in mind, markets have remained highly dovish, expecting a whopping six rate cuts this year from the Fed. All eyes will now turn towards the US employment data, with today's ADP payrolls figure leading into tomorrow's jobs report. With Fed member Barkin speculating that a soft-landing looks increasingly likely, a gradual deterioration in the payrolls and unemployment rate could help put pressure on the FOMC to cut rates in March."

Gold was quoted at USD2,047.78 an ounce at midday on Thursday, higher than USD2,038.89 on Wednesday.

By Greg Rosenvinge, Alliance News senior reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2024 Alliance News Ltd. All Rights Reserved.

More News
24 Apr 2024 17:06

CORRECT: No record close for FTSE 100; mixed trade in US

(Correcting day of the week in the opening sentence.)

Read more
24 Apr 2024 17:00

LONDON MARKET CLOSE: No record close for FTSE 100; mixed trade in US

(Alliance News) - Stock prices in London closed lower on Thursday, with the FTSE 100's recent rally taking a pause for breath, but not after hitting another record high.

Read more
24 Apr 2024 10:32

Angle shares jump on supplier agreement with with AstraZeneca

(Alliance News) - Angle PLC shares rose on Wednesday, after it signed a contract with AstraZeneca PLC.

Read more
24 Apr 2024 10:10

AIM WINNERS & LOSERS: Filtronic jumps as lifts outlook

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Wednesday.

Read more
22 Apr 2024 16:52

IN BRIEF: Angle granted patents in US and Europe for Cellkeep slide

Angle PLC - Surrey-based medical diagnostics provider - Says it has been granted a European and US patent for its CellKeep slide. "We are delighted to have secured intellectual property rights for our proprietary CellKeep slide in two major jurisdictions....This is a significant technology advancement for the [circulating tumor cell] liquid biopsy field and another step towards enabling biomarker-guided precision medicine for people with cancer," says Chief Executive Officer Andrew Newland. The CellKeep slide was developed by Angle to reduce cell loss during the transfer of CTCs to the microscope slide and to protect the morphology of the harvested cells.

Read more
22 Apr 2024 06:59

Angle granted European patent for CellKeep, US patent imminent

(Sharecast News) - Liquid biopsy specialist Angle announced on Monday that it has received a European patent for its 'CellKeep' slide, as it anticipated the imminent grant of an equivalent US patent application.

Read more
22 Jan 2024 18:03

IN BRIEF: Angle highlights supportive data for DNA analysis tool

Angle PLC - Surrey-based medical diagnostics provider - Announces publication of a peer-reviewed paper in a special issue of the journal - "Current Issues in Molecular Biology" Special Issue: Advanced Solutions for Cancer Therapy. Article brings together supporting evidence for the additional and complementary information that can be obtained from circulating tumour cells, demonstrating the value of a dual analyte approach for both CTCs and ctDNA (fragments of DNA released mainly by dying cells). Angle recently announced breakthrough data for real-time parallel next generation sequencing DNA analysis of both ctDNA and CTCs from a single tube of patient blood, using a pan-cancer panel run on an Illumina NGS system.

Read more
4 Jan 2024 16:54

LONDON MARKET CLOSE: Stocks up ahead of US nonfarm payrolls

(Alliance News) - Stock prices in London closed higher on Thursday, as investors eye the latest US non-farms data.

Read more
4 Jan 2024 12:19

Angle shares soar following "breakthrough" cancer diagnostics results

(Alliance News) - Angle PLC on Thursday said that "breakthrough results" from its latest blood sample cancer trials would allow it to expand its product sales and pharma services.

Read more
4 Jan 2024 10:43

AIM WINNERS & LOSERS: Angle soars on clinical tests; Likewise sales up

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Thursday.

Read more
4 Jan 2024 08:58

LONDON MARKET OPEN: Next leads buoyant FTSE 100 amid services PMIs

(Alliance News) - Stock prices in London opened up on Thursday, amid a slew of services PMI data, including for the UK, while reacting to the latest data from China.

Read more
4 Jan 2024 07:58

Angle receives 'breakthrough results' from DNA molecular analysis

(Sharecast News) - Liquid biopsy company Angle received "breakthrough results" from DNA molecular analysis of cancer patient blood samples on Thursday, sending its shares skywards as a result.

Read more
2 Jan 2024 09:04

Angle locks in $250,000 contract with Eisai

(Sharecast News) - Liquid biopsy company Angle has locked in a $250,000 contract with global pharmaceutical company Eisai to deliver circulating tumour cell analysis in a pilot study.

Read more
2 Jan 2024 08:51

IN BRIEF: Angle teams with Japan's Eisai in breast cancer drug trial

Angle PLC - Surrey, England-based medical diagnostics - Signs contract with Eisai Inc, part of Tokyo-based pharmaceutical firm Eisai Co Ltd. Under the agreement, the two will engage in a pilot study worth USD250,000 to Angle. Angle will provide circulating-tumour-cells analysis using its Portrait HER2 assay to assess the response of breast cancer patients to Eisai's BB-1701 antibody-drug conjugate. BB-1701 targets HER2, a protein that speeds up the growth of breast cancer cells. Success in the phase two pilot study will offer the possibility for multiple follow-up studies.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.